Since detection of abdominal and pelvic mesastasis by PSMA scan in October 2018, intermittant Lupron was very effective in keeping my cancer under control until July 2022.
From July 2022 until now I have been on continuous Lupron because PSA refused to become undetectable. From July 2022 until August 2023 my PSA hovered around 0.3. Then, from August 1 to November 1 (today) PSA jumped from 0.30 to 0.80 with a PSA doubling time less than 3 months. Since I am on continuous Lupron my T remained less than 20. I think I can assume that this increase in PSA is entirely due to Lupron resistant cancer cells.
Today I also had a PSMA scan. Highlights of the result of the scan are:
*Multiple PSMA-avid pelvic and retroperitoneal lymph nodes, some which have increased in size from prior CT Abdomen and Pelvis. Compared to prior PSMA PET/CT from 2018, however, some of these nodes demonstrate new radiotracer avidity, whereas, other nodes are no longer visualized on current examination.
* Left common iliac node (CT image 29), measuring 0.7 x 0.5 cm with SUV max of 11.6, previously PSMA-avid, and previoulsy measuring 0.5 x 0.3 cm on prior CT Abdomen and Pelvis.
* Retrocaval node (CT image 202), measuring 1.8 x 1.1 cm with SUV max of 38.4, previously PSMA-avid, and previously measuring 1.0 x 0.6 on prior CT Abdomen and Pelvis.
*Left para-aortic node (CT image 201), measuring 0.7 x 0.5 cm with SUV max of 11.1, previously not PSMA-avid, and previously measuring 0.9 x 0.4 cm on prior CT Abdomen and Pelvis.
The first and last paragraphs indicate that my cancer has spread to new lymph nodes not previously cancerous.
Now, the question is what are my treatment options. My MO would probably recommend adding Apalutamide to Lupron. Would adding Zytiga be a good option? Should we rule out chemo?